Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
HUTCHMED says its SANOVO trial demonstrated a progression-free survival benefit for ORPATHYS plus TAGRISSO in treatment-naïve patients with MET-overexpressing EGFR-mutated lung cancer in China.
Hutchmed said its SANOVO trial showed a progression-free survival benefit for ORPATHYS plus TAGRISSO in treatment-naïve patients with MET-overexpressing EGFR-mutated lung cancer in China.